If you or a family member have myotonic dystrophy, the #1 thing you can do to help researchers develop an effective treatment is to enroll in the END-DM1 natural history study. Details here: https://t.co/pufFFBh0Fx
French pub: Atteinte cognitive dans la maladie de Steinert de l'adulte : de nouvelles données venues du Nord [Cognitive involvement in adult myotonic dystrophy type 1: new findings from the North] https://t.co/UsWwnWHlJO
MDF’s new DM1 and DM2 Guides are here! 💚
We’ve reworked and expanded our previous toolkit to create guides for people living with #MyotonicDystrophy, their caregivers, and loved ones.
Explore practical information about DM, medical care, and daily life.
At PepGen, we value providing the DM1 community with timely and transparent updates on our progress. Today we announced interim results from the FREEDOM2-DM1 clinical trial.
Read our latest letter to the DM1 community here: https://t.co/O0bCw6z6BX
Thank you to those who have participated in trials, are considering participation, or supporting loved ones. Our work is not possible without you.
#myotonicdystrophy #DM1
Greek review: Nonpharmacological and rehabilitative interventions for adults with myotonic dystrophy type 1: a systematic review https://t.co/wzaEM0wOSP
Norwegian study: Muscle Strength and Outcome Measures for Upper Limb Function in Adults With Myotonic Dystrophy Type 1: A Cross-Sectional Study https://t.co/5efVts87an
Share your thoughts on #myotonicDystrophy clinical trials with a 5-minute survey! Your feedback will help MDF understand what information is most important to the DM community as trials continue to develop. https://t.co/b5YSumuSN3
NY study: Sympathetic neurons’ contribution to arrhythmias in a hiPSC-based myotonic dystrophy type 1 microphysiological system https://t.co/usOhBjOyNP